Cocrystal Pharma, Inc.
Clinical trials sponsored by Cocrystal Pharma, Inc., explained in plain language.
Biotech developing antiviral drugs for influenza and hepatitis.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill aims to stop stomach bug in its tracks Results expected Oct 2026 (estimated)
-
New flu pill passes first safety hurdle in small human study
Disease control CompletedThis early-phase study tested a new oral drug called CC-42344 in 80 healthy adults to see if it is safe and how the body processes it. The drug is designed to stop the influenza A virus from multiplying. The study did not treat actual flu patients, but the results will help decid…
Phase 1 • Sponsor: Cocrystal Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Could a new pill block COVID-19's spread? a first human trial begins
Prevention CompletedThis early-stage trial is testing an experimental oral drug called CDI-988 in healthy adults to see if it is safe and how it behaves in the body. CDI-988 is designed to block a key enzyme that the COVID-19 virus needs to multiply. Participants are randomly assigned to receive eit…
Phase 1 • Sponsor: Cocrystal Pharma, Inc. • Aim: Prevention
Last updated Aug 21, 2026 00:00 UTC